IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients

Palmieri, C, Stein, RC, Liu, X et al. (12 more authors) (2017) IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients. Breast Cancer Research and Treatment, 165 (2). pp. 343-353. ISSN 0167-6806

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © The Author(s) 2017. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Keywords: Breast cancer; Endocrine therapy; Sulfatase; Aromatase
Dates:
  • Published: September 2017
  • Accepted: 1 June 2017
  • Published (online): 13 June 2017
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 23 Jan 2018 12:00
Last Modified: 26 Jul 2018 13:04
Status: Published
Publisher: Springer Nature
Identification Number: https://doi.org/10.1007/s10549-017-4328-z

Commentary/Response Threads

Download

Share / Export

Statistics